Single Ascending Dose Study of RBP-6000

Completed · Phase 1

Conditions studied: Opioid Use Disorder

In brief

A multi-center, open-label, single ascending dose study to enroll opioid dependent treatment-seeking subjects. Subjects to be enrolled into 3 cohorts receiving low, medium and high doses of depot buprenorphine. A fourth cohort will be enrolled to evaluate the PK of RBP-6000 after receiving suboxone tablets for 7 days.

Key facts

Study ID

NCT03002961

Run by

Indivior Inc.

People needed

48

Starts

2012-07-01

Expected to finish

2013-10-01

Last updated by the study team

2016-12-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Sex: male and female subjects are eligible for entry.
• Age: ≥ 18 to ≤ 65 years.
• Body mass index (BMI) of ≥ 18.0 to ≤ 33.0 kg/m2
• Female subjects must have a negative pregnancy test. Women of child bearing potential should have been surgically sterile for at least 6 months prior to dosing or must agree to take reasonable precautions during the study to avoid pregnancy by agreeing to remain abstinent or to practice one of the following methods of birth control from study screening through the last study visit: double barrier (e.g., diaphragm with spermicide; condoms with spermicide); intrauterine device (IUD); implanted or intrauterine hormonal contraceptives in use for at least 6 consecutive months prior to study dosing; or oral, patch, or injected contraceptives or vaginal hormonal device in use for at least 3 consecutive months prior to study.
• Meet DSM-IV-TR criteria for opioid dependence and are seeking opioid-dependence treatment.
• (Note: Subjects need not to be seeking treatment with methadone but be willing to accept methadone treatment as consequence of the study.)
• Normal or no clinically significant electrocardiogram (ECG) findings at screening or through predose on Day 1.
• Total bilirubin ≤ 2x the upper limit of normal (ULN), alanine aminotransferase (ALT) ≤ 2xULN, aspartate aminotransferase (AST) ≤ 2xULN, serum creatinine ≤ 2xULN, and international normalized ratio (INR) ≤ 2xULN.
• Agree not to take any buprenorphine products other than those administered for the current study (SUBOXONE SL tablets and RBP-6000) throughout participation in the study.
• Willing to cooperate with study procedures and provide written informed consent prior to start of any study procedures.

You may not qualify if…

• Require ongoing opioid therapy for pain or other chronic medical conditions.
• ECG demonstrating QTc > 450 msec in males and QTc > 470 msec in females at clinic entry or prior to administration of RBP-6000.
• Currently dependent by DSM-IV-TR criteria on any substances other than opioids, caffeine, or nicotine.
• Currently (during past 30 days from the signing of the informed consent document) engaged in opioid agonist, partial agonist, or antagonist treatment; or require on-going prescription or over the counter (OTC) medications that are clinically relevant CYP P450 3A4 inducers or inhibitors (e.g., rifampicin, azole antifungals [e.g., ketoconazole], macrolide antibiotics [e.g., erythromycin]). See Appendix 12 for an excluded medications list.
• Significant traumatic injury, major surgery, or open biopsy within the prior 4 weeks of informed consent.
• Buprenorphine use within 30 days of informed consent.
• Subjects with a COWS score of < 12 on the day of administration of RBP-6000 (Applicable for subjects in Cohort 1-3 only, subjects for cohort 4 will not be excluded with a COWS score <12).
• Subjects with any history of suicidal ideation within 30 days prior to informed consent or study drug administration as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the C-SSRS completed at the screening visit, or any history of suicide attempts.
• Clinically significant abnormality in past medical history or at the screening physical examination that in the opinion of the PI or Sponsor may place the volunteer at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of drug, including but is not limited to history or concurrent cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease.
• History or presence of allergic or adverse response (including rash or anaphylaxis) to buprenorphine, naloxone, methadone, or the ATRIGEL Delivery System.
• Donation of> 250 mL of blood or plasma or participation in another clinical trial within 30 days prior to signing of the informed consent document for this study.
• Current use of or positive urine screen at clinic admission for barbiturates, benzodiazepines, buprenorphine, or methadone.
• Serology positive for human immunodeficiency virus (HIV), acute hepatitis B, or acute hepatitis C and subjects positive for both hepatitis B surface antigen (HBsAg) and immunoglobulin M antibodies to hepatitis B core antigen (anti-HBc IgM). (Note: Subjects with asymptomatic hepatitis B or C infection may be enrolled.)
• All herbal supplements, grapefruit and grapefruit juices, and OTC medications. Sponsor may allow exceptions of medicines that are unlikely to impact PK or PD results.
• Subjects who have been previously excluded from participation or previously enrolled into the study or have previously participated in a study with RBP-6000.
• Subjects who are unable, in the opinion of the PI or the medically responsible physician, to comply fully with the study requirements

Where it is running

• Vince and Associates Clinical Research — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.